<DOC>
	<DOC>NCT00264017</DOC>
	<brief_summary>In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.</brief_summary>
	<brief_title>Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis</brief_title>
	<detailed_description />
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Males age 4580 years Diagnosis of prostate cancer Status post IMRT and Palladium103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation Baseline AUA score&lt; or =12 May be on antiandrogenand/or alpha reductase therapy Patients receiving IMRT followed by Palladium103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent History of insulindependent diabetes Uncontrolled hypertention History of symptomtic hypotension (including syncope and dizziness) Preexisting obstructive uropathy based on history of BPH and or Acute Urinary Retention Preexisting prostatitis either continuous or intermittent Concurrent use of any other anticholinergics previous or concurrent usage of LHRH agonist</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>